Summary
Moderna's share price has doubled following successful trial results for its melanoma cancer vaccine, which is being developed in collaboration with Merck.
Moderna Share Price Doubles After Successful Melanoma Vaccine Trial
HyperFast News
Related news
Moderna Stock Plunges 25%, Wiping Out $18 Billion Despite Cancer Vaccine Breakthrough
18 Sept 2026, 8:55 pm · News
Moderna's 177% Surge Causes $5.5 Billion Loss for Short Sellers
18 Sept 2026, 8:55 pm · News
Moderna co-founder Robert Langer is a billionaire again as stock more than doubles
18 Sept 2026, 8:55 pm · News
